Capricor CEO says Deramiocel unlikely to get conditional approval

Capricor Therapeutics stock is heading for its best week in nearly a month as CEO Linda Marban dismissed concerns that its Duchenne muscular dystrophy therapy Deramiocel could receive only conditional approval. The FDA has accepted the company application with an August 22 decision date, while Capricor prepares for a potential launch.